Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome - PubMed (original) (raw)
Comparative Study
. 2006 Dec;4(12):2569-75.
doi: 10.1111/j.1538-7836.2006.02205.x. Epub 2006 Sep 12.
Affiliations
- PMID: 16968329
- DOI: 10.1111/j.1538-7836.2006.02205.x
Free article
Comparative Study
Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome
J J J Hulstein et al. J Thromb Haemost. 2006 Dec.
Free article
Abstract
Background: HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome is a severe complication of pre-eclampsia in pregnancy, characterized by microvascular platelet thrombi. Activation of the endothelium is thought to play a key role in pre-eclampsia and HELLP syndrome. Activation of endothelial cells may lead to release of von Willebrand factor (VWF) multimers, which are highly reactive with platelets. Normally, newly released multimers are cleaved by ADAMTS13, resulting in less reactive derivatives.
Objective: We hypothesized that HELLP syndrome is characterized by increased amounts of active VWF compared with healthy pregnancy and pre-eclampsia, due to acute activation of endothelial cells. This might contribute to thrombocytopenia and thrombotic microangiopathy.
Methods: Active VWF and ADAMTS13 activity were measured in healthy pregnant volunteers (n = 9), patients with pre-eclampsia (n = 6) and patients with HELLP syndrome (n = 14) at similar gestational ages. To study the role of endothelial cell activation, the propeptide/mature VWF ratio was determined, and VWF released by cultured endothelial cells was analyzed.
Results: Active VWF levels were increased 2.1-fold in HELLP syndrome compared with healthy pregnant volunteers (P < 0.001) and 1.6-fold compared with patients with pre-eclampsia (P = 0.001). ADAMTS13 activity was moderately decreased in patients with HELLP syndrome compared with healthy pregnant volunteers (P < 0.004), but not compared with patients with pre-eclampsia. The propeptide/mature VWF ratio was increased 1.7-fold compared with healthy pregnant volunteers (P < 0.001) and 1.5-fold compared with patients with pre-eclampsia (P < 0.05). A significant correlation was found between this ratio and the activation factor of VWF (r = 0.68, P < 0.001). The amount of active VWF was increased 1.4-fold in medium of stimulated endothelial cells when compared with non-stimulated cells (P < 0.05).
Conclusion: Acute endothelial cell activation in HELLP syndrome and decreased ADAMTS13 activity result in increased amounts of active VWF. This might explain the consumptive thrombocytopenia and thrombotic microangiopathy associated with HELLP syndrome. Inhibition of circulating active VWF could be a potential new approach in the treatment of patients with HELLP syndrome.
Similar articles
- Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.
Molvarec A, Rigó J Jr, Bõze T, Derzsy Z, Cervenak L, Makó V, Gombos T, Udvardy ML, Hársfalvi J, Prohászka Z. Molvarec A, et al. Thromb Haemost. 2009 Feb;101(2):305-11. Thromb Haemost. 2009. PMID: 19190814 - Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
Casonato A, Pontara E, Morpurgo M, Sartorello F, De Groot PG, Cattini MG, Daidone V, De Marco L. Casonato A, et al. Br J Haematol. 2015 Dec;171(5):845-53. doi: 10.1111/bjh.13785. Epub 2015 Oct 12. Br J Haematol. 2015. PMID: 26456374 - Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.
Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM. Lattuada A, et al. Haematologica. 2003 Sep;88(9):1029-34. Haematologica. 2003. PMID: 12969811 - Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
Budde U, Schneppenheim R. Budde U, et al. Hamostaseologie. 2014;34(3):215-25. doi: 10.5482/HAMO-13-08-0045. Epub 2014 Jul 10. Hamostaseologie. 2014. PMID: 25010251 Review. - Molecular Advances in Preeclampsia and HELLP Syndrome.
Gardikioti A, Venou TM, Gavriilaki E, Vetsiou E, Mavrikou I, Dinas K, Daniilidis A, Vlachaki E. Gardikioti A, et al. Int J Mol Sci. 2022 Mar 31;23(7):3851. doi: 10.3390/ijms23073851. Int J Mol Sci. 2022. PMID: 35409211 Free PMC article. Review.
Cited by
- HELLP Syndrome-Holistic Insight into Pathophysiology.
Petca A, Miron BC, Pacu I, Dumitrașcu MC, Mehedințu C, Șandru F, Petca RC, Rotar IC. Petca A, et al. Medicina (Kaunas). 2022 Feb 21;58(2):326. doi: 10.3390/medicina58020326. Medicina (Kaunas). 2022. PMID: 35208649 Free PMC article. Review. - Innate and Adaptive Immune Responses in HELLP Syndrome.
Stojanovska V, Zenclussen AC. Stojanovska V, et al. Front Immunol. 2020 Apr 15;11:667. doi: 10.3389/fimmu.2020.00667. eCollection 2020. Front Immunol. 2020. PMID: 32351511 Free PMC article. Review. - The BPH/5 Mouse Model of Superimposed Preeclampsia Is Not a Model of HELLP Syndrome.
Johnston AN, Batts TL, Langohr IM, Moeller C, Liu CC, Sones JL. Johnston AN, et al. Biology (Basel). 2021 Nov 14;10(11):1179. doi: 10.3390/biology10111179. Biology (Basel). 2021. PMID: 34827172 Free PMC article. - Analytical characterization and reference interval of an enzyme-linked immunosorbent assay for active von Willebrand factor.
van der Vorm LN, Li L, Huskens D, Chayouâ W, Kelchtermans H, de Groot PG, Roest M, Remijn JA, de Laat B. van der Vorm LN, et al. PLoS One. 2019 Feb 13;14(2):e0211961. doi: 10.1371/journal.pone.0211961. eCollection 2019. PLoS One. 2019. PMID: 30759116 Free PMC article. - Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome.
Yoshida Y, Matsumoto M, Yagi H, Isonishi A, Sakai K, Hayakawa M, Hori Y, Sado T, Kobayashi H, Fujimura Y. Yoshida Y, et al. Blood Adv. 2017 Aug 23;1(20):1628-1631. doi: 10.1182/bloodadvances.2017006767. eCollection 2017 Sep 12. Blood Adv. 2017. PMID: 29296808 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous